- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Di | Novartis CEO calls for 'complete rethink' of Europe's drug pricing policies | ||
| Di | Pfizer's victory in delaying Vyndamax generics is mixed bag for BridgeBio: analysts | ||
| Di | FDA flags concerns for AstraZeneca's camizestrant, Truqap ahead of advisory committee meeting | ||
| Di | FDA turns up heat on Amgen, proposing to rescind approval of Tavneos | ||
| Di | Rocket sells priority review voucher for $180M after Kresladi gene therapy approval | ||
| Di | AstraZeneca's Breztri nabs FDA asthma nod, adding fuel to blockbuster launch | ||
| Di | Haleon scores branding goal with star-studded soccer offensive | ||
| Di | Novartis stands by $5B Pluvicto goal despite European regulatory setback, bispecific competition | ||
| Mo | Mundipharma, CorMedix eye antifungal expansion after Rezzayo trial win | ||
| Mo | Astellas counts on new medicines to offset projected Xtandi decline in fiscal 2026 | ||
| Mo | Pfizer settles with 2 generic Vyndamax makers in latest twist to ATTR market: analysts | ||
| Mo | Haleon nabs Google exec Richard Manso as US chief marketing officer | ||
| Mo | Sun Pharma strikes biopharma's largest deal of '26 with $11.75B buyout of Organon | ||
| Mo | Ligand snaps up fellow biotech royalty aggregator Xoma for $739M | ||
| 24.04. | FDA snubs AbbVie's prospective Botox heir amid series of manufacturing-related CRLs | ||
| 24.04. | Sanofi gains long-awaited win for tolebrutinib as EU regulator endorses MS drug for approval | ||
| 24.04. | Daiichi pushes back annual report, citing reviews amid 'rapidly changing business conditions' | ||
| 24.04. | Travere's launchpad positions Filspari for fast rise toward blockbuster sales: analyst | ||
| 24.04. | Genentech wants 'All Eyes on DME' as it taps Damon Wayans for humor-laced campaign | ||
| 24.04. | Pfizer's cost-cutting push reaches Ireland again as it plans manufacturing layoffs | ||
| 24.04. | Pfizer drafts Fernando Mendoza as new face of its 'game of inches' cancer campaign | ||
| 24.04. | Fierce Pharma Asia-Merck's PD-1xVEGF data; Zai Lab's global view; Kailera's record IPO | ||
| 24.04. | Patients less confident than ever about health choices: survey | ||
| 23.04. | Regeneron ushers in new genetic medicine era with groundbreaking gene therapy approval | ||
| 23.04. | Despite data concerns, Roche's oral SERD can still be largest product in company history: exec |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.